Ortho Clinical Diagnostics (OCDX) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.19 per share a year ago.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

(Reuters) - Private equity firm Carlyle Group LP (CG.O) is exploring a sale or initial public offering of Ortho-Clinical Diagnostics Inc, a U.S. diagnostics company that could be valued at more than ...

Aligned with its mission to improve and save lives with diagnostics, Ortho Clinical Diagnostics today announced it is launching to market its SARS-CoV-2 (COVID-19/coronavirus) antibody test—the VITROS ...

RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ...

Ortho Clinical Diagnostics Holdings plc, an in-vitro diagnostics company, has raised $1.3 billion for its IPO after pricing its 76 million shares at $17 per share. The stock began trading January 28, ...

Unlike many commercially available antibody test kits, Ortho’s automated VITROS ® Anti-SARS-CoV-2 antibody tests are highly reliable and have demonstrated 100% specificity in assay validation studies.

- Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians ...

RARITAN, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient ...

Carlyle Group is exploring a sale or initial public offering of Ortho-Clinical Diagnostics, which could be valued at more than $7 billion, including debt. A divestment of Ortho-Clinical Diagnostics ...